Table 2.
Baseline characteristics according to the presence of CSVD when grouped by infarction number
| Characteristics | NAI(n=283) | SAI(n=398) | MAIs(n=205) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Non-CSVD (n=58) |
CSVD (n=225) |
p value | Non-CSVD (n=86) |
CSVD (n=312) |
p value | Non-CSVD (n=50) |
CSVD (n=155) |
p value | |
| Age, years, median(IQR) | 56.5(48.1–62.3) | 66.1(59.5–73.3) | <0.001 | 57.1(50.3–63.1) | 62.9(55.3–71.2) | <0.001 | 58.6(51.7–67.5) | 64.9(56.8–74.2) | <0.001 |
| BMI, kg/m2, median (IQR) | 24.6(22.4–26.8) | 24.2(22.0–26.3) | 0.26 | 24.3(23.0–26.4) | 24.5(22.5–26.1) | 0.50 | 25.1(22.9–26.7) | 24.1(21.5–26.0) | 0.04 |
| Sex, male (%) | 34(66.2) | 149(66.2) | 0.28 | 59(68.6) | 211(67.6) | 0.86 | 35(70.7) | 102(65.8) | 0.58 |
| Alcohol use, n (%) | 20(34.5) | 68(30.2) | 0.53 | 28(32.6) | 100(32.1) | 0.93 | 20(40.0) | 46(29.7) | 0.17 |
| Tobacco use, n (%) | 25(43.1) | 88(39.1) | 0.58 | 43(50.0) | 136(43.6) | 0.29 | 24(48.0) | 72(46.5) | 0.85 |
| History of disease, n (%) | |||||||||
| Ischaemic stroke | 2(3.5) | 40(17.8) | 0.006 | 8(9.3) | 60(19.2) | 0.03 | 7(14.0) | 29(18.7) | 0.45 |
| TIA | 3(5.2) | 2(0.89) | 0.03 | 1(1.2) | 7(2.2) | 0.53 | 1(2.0) | 7(4.5) | 0.42 |
| Myocardial infarction | 1(1.7) | 7(3.1) | 0.57 | 0(0) | 6(1.9) | 0.20 | 2(4.0) | 3(1.9) | 0.41 |
| Congestive heart failure | 1(1.7) | 4(1.8) | 0.98 | 1(1.2) | 1(0.3) | 0.33 | 2(4.0) | 7(4.5) | 0.88 |
| Atrial fibrillation | 1(1.7) | 8(3.6) | 0.48 | 1(1.2) | 5(1.6) | 0.77 | 1(2.0) | 5(3.2) | 0.65 |
| Diabetes mellitus | 8(13.8) | 37(16.4) | 0.62 | 15(17.4) | 75(24.0) | 0.20 | 13(26.0) | 35(22.6) | 0.62 |
| Hypertension | 25(43.1) | 158(70.2) | 0.001 | 39(45.4) | 215(68.9) | <0.001 | 29(58.0) | 103(66.5) | 0.28 |
| Hyperlipidemia | 7(12.1) | 28(12.4) | 0.94 | 9(10.5) | 39(12.5) | 0.61 | 5(10.0) | 22(14.2) | 0.45 |
| ICAS | 30(51.7) | 116(51.8) | 0.99 | 35(340.7) | 137(43.9) | 0.59 | 40(80.0) | 101(65.2) | 0.05 |
| NIHSS score on admission, median(IQR) | 1(0–1) | 1(0–2) | 0.45 | 2(1–3) | 2(1–3) | 0.37 | 2(1–3) | 2(1–3) | 0.17 |
| Mean time to randomisation, hour, median(IQR) | 13.4(8.0–20.0) | 12.0(8.0–20.0) | 0.81 | 11.4(7.0–18.5) | 13.0(8.5–12.1) | 0.04 | 10.0(6.6–17.3) | 12.2(7.0–20.5) | 0.22 |
| Qualifying event, N (%) | 0.19 | 0.55 | 0.42 | ||||||
| Minor stroke | 40(69.0) | 18(31.0) | 78(90.7) | 289(92.6) | 42(84.0) | 137(88.4) | |||
| TIA | 174(77.3) | 51(22.7) | 8(9.3) | 23(7.4) | 8(16.0) | 18(11.6) | |||
| Antiplatelet therapy, n (%) | 0.66 | 0.27 | 0.44 | ||||||
| Aspirin only | 28(48.3) | 116(51.6) | 40(46.5) | 166(53.2) | 27(54.0) | 74(47.7) | |||
| Clopidogrel+aspirin | 30(51.7) | 109(48.4) | 46(53.4) | 146(46.8) | 23(46.0) | 81(52.3) | |||
BMI, body mass index; TIA, transient ischaemic attack; NIHSS, National Institutes of Health Stroke Scale; ICAS, Intracranial atherosclerotic stenosis; CSVD, cerebral small vessel disease; NAI, non-acute infarction; SAI, single acute infarction; MAIs, multiple acute infarctions.